Skip to main content

Table 1 Formulation of Product

From: Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial

Dose Groups

Peptides loaded / HLA class

Peptide loading method and concentration

DEX dose (expressed as numbers of MHC class II molecules)

A

MAGE A3 (168–176) / class I

Indirect (10 μg/mL)

0.13 Ă— 1014

 

MAGE A3 (247–258) / class II

Indirect (10 μg/mL)

 
 

tetanus toxoid / class II

Indirect (10 μg/mL)

 

B

MAGE A3 (168–176) / class I

Indirect (10 μg/mL)

0.4 Ă— 1014

 

MAGE A3 (247–258) / class II

Indirect (10 μg/mL)

 

C

MAGE A3 (168–176) / class I

Direct (10 μg/mL)

0.13 Ă— 1014

 

MAGE A3 (247–258) / class II

Indirect (10 μg/mL)

 
 

tetanus toxoid / class II

Indirect (10 μg/mL)

 

D

MAGE A3 (168–176) / class I

Direct (100 μg/mL)

0.13 Ă— 1014

 

MAGE A3 (247–258) / class II

Indirect (10 μg/mL)

Â